Format

Send to

Choose Destination
Blood Cancer J. 2018 Sep 3;8(9):88. doi: 10.1038/s41408-018-0122-3.

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.

Author information

1
Cardiff University, Cardiff, Wales, UK. ottmanno@cardiff.ac.uk.
2
University of Turin, Turin, Italy.
3
Imperial College, London, UK.
4
Royal North Shore Hospital, Sydney, NSW, Australia.
5
Hospital Britanico, Buenos Aires, Argentina.
6
Institut Paoli-Calmettes, Marseille, France.
7
Washington University School of Medicine, St. Louis, MO, USA.
8
The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
9
Winship Cancer Institute, Emory University, Atlanta, GA, USA.
10
Catholic Hematology Hospital, Seoul St. Mary's Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea.
11
Bristol-Myers Squibb, Princeton, NJ, USA.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center